17 interviews and contributions

Interviews and media contributions.

These articles and interviews cover GLP-1 access, affordability and what patients actually go through. Some include my perspective as a patient or an advocate. For others I helped a journalist reach patients who wanted to tell their own story. Each entry says which it was.

2026

6 features
  • Feb 5, 2026

    KXCR Community Radio (Oregon) ↗

    Oregon lags behind most states in GLP-1 use

    Interviewed on air

  • Feb 23, 2026

    The New York Times ↗

    Exercise and weight-loss drugs

    Helped connect patients with the reporter

  • Apr 2, 2026

    Business Insider ↗

    She lost 100 pounds on Zepbound. Then her insurance cut her off

    Background interview on GLP-1 insurance coverage, and connected patients for interviews

  • Apr 2026

    WLRN (South Florida Public Media)

    GLP-1 access in Florida

    Interviewed

  • Jul 6, 2026

    NBC News ↗

    Whether GLP-1s are worth the cost

    Background interview by phone, and connected a patient for the story

  • Aug 24, 2026

    Marketplace Morning Report (APM) ↗

    Fewer employers are covering GLP-1 drugs for weight loss. Should they?

    Interviewed on the cost of staying on GLP-1s and safer ways to access them

2025

7 features
  • Mar 2, 2025

    USA Today ↗

    FDA decisions on compounded GLP-1 medications

    Quoted as a patient source on compounded medications

  • Mar 5, 2025

    Childhood Obesity News ↗

    FDA ends compounding for popular GLP-1 drugs

    Advocacy work cited in the article

  • Mar 12, 2025

    Fast Company ↗

    Compounded Wegovy and Zepbound may disappear under new FDA rules

    Quoted as a patient source on regulatory changes

  • Apr 1, 2025

    KRLD NewsRadio 1080 (Audacy) ↗

    FDA bans compounded weight-loss drugs

    Interviewed on air about the compounding decision

  • May 14, 2025

    Wired ↗

    GLP-1 copycats and the compounded medication landscape

    Quoted as a patient source on compounded medications

  • May 23, 2025

    Reuters ↗

    Amid compounding crackdown, US patients struggle as weight-loss drug discounts fall

    Interviewed as a patient about access to compounded medications

  • Oct 20, 2025

    Danish Broadcasting Corporation (DR) ↗

    On Novo Nordisk litigation and patient advocacy concerns

    Interviewed as a patient advocate on Novo Nordisk litigation

2024

4 features
  • Nov 26, 2024

    Politico Prescription Pulse ↗

    On GLP-1 patient petitions to the FDA

    Quoted as a patient source on the national access petition

  • Dec 1, 2024

    USA Today ↗

    High prices push consumers to seek weight-loss drug alternatives

    Quoted as a patient source on medication affordability

  • Dec 19, 2024

    ABC Local 5 News (Iowa) ↗

    Urging FDA to support GLP-1 compounding alternatives

    Interviewed as a patient advocate on the petition

  • Dec 24, 2024

    CNBC ↗

    FDA Zepbound shortage impact and patient alternatives

    Quoted as a patient source on access